| Symbol | MIRM |
|---|---|
| Name | MIRUM PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 950 TOWER LANE,SUITE 1050, FOSTER CITY, California, 94404, United States |
| Telephone | +1 650 667-4085 |
| Fax | — |
| — | |
| Website | https://www.mirumpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001759425 |
| Description | Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Additional info from NASDAQ: |
2026-07-02 22:01
Howe Jolanda 🔴 sold 2.7K shares of Mirum Pharmaceuticals, Inc. (MIRM) at $120.00 Transaction Date: Jul 01, 2026 | Filing ID: 000010
Read more
2026-06-18 22:39
Howe Jolanda 🔴 sold 2.6K shares of Mirum Pharmaceuticals, Inc. (MIRM) at $101.95 Transaction Date: Jun 17, 2026 | Filing ID: 000009
Read more
2026-06-18 00:30
Walbert Timothy P 🟢 acquired 5.8K shares (2 derivative) of Mirum Pharmaceuticals, Inc. (MIRM) at $101.00 Transaction Date: Jun 15, 2026 | Filing ID: 000004
Read more
2026-06-18 00:30
Cardon Lon 🟢 acquired 5.8K shares (2 derivative) of Mirum Pharmaceuticals, Inc. (MIRM) at $101.00 Transaction Date: Jun 15, 2026 | Filing ID: 000004
Read more
2026-06-18 00:30
Ramasastry Saira 🟢 acquired 5.8K shares (2 derivative) of Mirum Pharmaceuticals, Inc. (MIRM) at $101.00 Transaction Date: Jun 15, 2026 | Filing ID: 000016
Read more
2026-06-18 00:30
Fairey William 🟢 acquired 5.8K shares (2 derivative) of Mirum Pharmaceuticals, Inc. (MIRM) at $101.00 Transaction Date: Jun 15, 2026 | Filing ID: 000004
Read more
2026-06-18 00:30
Brege Laura 🟢 acquired 5.8K shares (2 derivative) of Mirum Pharmaceuticals, Inc. (MIRM) at $101.00 Transaction Date: Jun 15, 2026 | Filing ID: 000005
Read more
2026-06-18 00:30
Heron Patrick J 🟢 acquired 5.8K shares (2 derivative) of Mirum Pharmaceuticals, Inc. (MIRM) at $101.00 Transaction Date: Jun 15, 2026 | Filing ID: 000004
Read more
2026-06-18 00:30
Fischer Laurent 🟢 acquired 5.8K shares (2 derivative) of Mirum Pharmaceuticals, Inc. (MIRM) at $101.00 Transaction Date: Jun 15, 2026 | Filing ID: 000005
Read more
2026-06-18 00:30
GREY MICHAEL G 🟢 acquired 5.8K shares (2 derivative) of Mirum Pharmaceuticals, Inc. (MIRM) at $101.00 Transaction Date: Jun 15, 2026 | Filing ID: 000005
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04530994 | A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus As… | — | Alagille Syndrome | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07411716 | Pediatric Evaluation and Registry for Liver Cholestasis in Canada | — | PFIC - Progressive Familial Intrahepatic Cholestasis | Recruiting | 2026-04-21 | 2031-12-01 | ClinicalTrials.gov |
| NCT07389031 | Maralixibat for Intrahepatic Cholestasis of Pregnancy | Phase2 | Intrahepatic Cholestasis of Pregnancy | Not_Yet_Recruiting | 2026-04-01 | 2028-03-31 | ClinicalTrials.gov |
| NCT07454837 | Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participa… | Phase2 | Chronic Hepatitis D | Recruiting | 2026-02-26 | 2029-03-30 | ClinicalTrials.gov |
| NCT07298330 | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic… | Phase3 | Chronic Hepatitis D Infection | Active_Not_Recruiting | 2026-01-14 | 2029-01-01 | ClinicalTrials.gov |
| NCT07209462 | Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) | Phase2 | Fragile X Syndrome | Recruiting | 2025-11-22 | 2027-10-01 | ClinicalTrials.gov |
| NCT07290257 | Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmA… | Phase4 | Alagille Syndrome | Recruiting | 2025-09-25 | 2030-12-22 | ClinicalTrials.gov |
| NCT07200908 | A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chr… | Phase3 | Chronic Hepatitis D Infection | Recruiting | 2025-08-27 | 2029-09-30 | ClinicalTrials.gov |
| NCT06907290 | A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic He… | Phase2 | Chronic Hepatitis D Infection | Active_Not_Recruiting | 2025-03-25 | 2029-09-01 | ClinicalTrials.gov |
| NCT06553768 | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver… | Phase3 | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Active_Not_Recruiting | 2024-10-14 | 2027-02-01 | ClinicalTrials.gov |
| NCT06193928 | Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United St… | — | Alagille Syndrome | Recruiting | 2023-09-21 | 2030-09-20 | ClinicalTrials.gov |
| NCT05050136 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixi… | Phase2 | Primary Biliary Cholangitis | Recruiting | 2021-09-22 | 2027-07-01 | ClinicalTrials.gov |
| NCT04729751 | A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Partic… | Phase2 | Progressive Familial Intrahepatic Cholestasis | Completed | 2021-09-09 | 2024-12-17 | ClinicalTrials.gov |
| NCT04524390 | Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai | Phase2 | Biliary Atresia | Completed | 2021-07-08 | 2024-02-07 | ClinicalTrials.gov |
| NCT05368038 | ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | — | Acid Sphingomyelinase Deficiency | Enrolling_By_Invitation | 2021-05-10 | 2029-08-31 | ClinicalTrials.gov |
| NCT04718961 | A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Ac… | Phase2 | Intrahepatic Cholestasis of Pregnancy | Terminated | 2021-01-04 | 2022-12-07 | ClinicalTrials.gov |
| NCT04663308 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixi… | Phase2 | Primary Sclerosing Cholangitis | Active_Not_Recruiting | 2020-12-18 | 2027-04-01 | ClinicalTrials.gov |
| NCT04270682 | Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) | Phase3 | CTX | Completed | 2020-01-31 | 2023-10-04 | ClinicalTrials.gov |
| NCT04168385 | MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestati… | Phase2 | Cholestatic Liver Disease | Completed | 2020-01-16 | 2024-09-04 | ClinicalTrials.gov |
| NCT04185363 | An Extension Study of Maralixibat in Patients With Progressive Familial Intrahe… | Phase3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Completed | 2020-01-08 | 2025-04-23 | ClinicalTrials.gov |
| NCT03905330 | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Pro… | Phase3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Completed | 2019-07-09 | 2022-09-01 | ClinicalTrials.gov |
| NCT03353454 | A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With P… | Phase3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Withdrawn | 2018-10-25 | 2020-06-15 | ClinicalTrials.gov |
| NCT03115086 | The REPLACE Registry for Cholbam® (Cholic Acid) | — | Bile Acid Synthesis Disorders | Active_Not_Recruiting | 2017-07-10 | 2039-07-01 | ClinicalTrials.gov |
| NCT02787304 | Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis… | Phase2 | Non-Alcoholic Steatohepatitis | Terminated | 2016-10-24 | 2018-07-27 | ClinicalTrials.gov |
| NCT02571192 | A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body Af… | Phase1 | Non-Alcoholic Steatohepatitis | Completed | 2015-10-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02475317 | Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP62… | Phase1 | Healthy Volunteers | Completed | 2015-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02321306 | An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001… | Phase2 | Primary Biliary Cirrhosis | Withdrawn | 2015-05-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02117713 | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of… | Phase2 | Alagille Syndrome | Completed | 2015-03-16 | 2020-06-01 | ClinicalTrials.gov |
| NCT02287779 | Safety and Tolerability Study of SHP626 in Overweight and Obese Adults | Phase1 | Non-Alcoholic Steatohepatitis | Completed | 2015-01-19 | 2015-06-19 | ClinicalTrials.gov |
| NCT02057692 | Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome | Phase2 | Alagille Syndrome | Completed | 2014-11-24 | 2016-11-16 | ClinicalTrials.gov |
| NCT02160782 | Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period… | Phase2 | Alagille Syndrome | Completed | 2014-10-28 | 2020-05-28 | ClinicalTrials.gov |
| NCT02131623 | Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestat… | — | Alagille Syndrome | Completed | 2014-07-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02057718 | Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixib… | Phase2 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Completed | 2014-03-01 | 2020-05-08 | ClinicalTrials.gov |
| NCT02061540 | Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Pri… | Phase2 | Primary Sclerosing Cholangitis (PSC) | Completed | 2014-03-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02047318 | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of… | Phase2 | Alagille Syndrome | Completed | 2013-12-20 | 2020-06-17 | ClinicalTrials.gov |
| NCT01904058 | Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Pa… | Phase2 | PBC | Completed | 2013-08-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01903460 | Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disea… | Phase2 | Alagille Syndrome | Completed | 2013-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01115582 | Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children Wi… | Phase3 | Inborn Errors of Bile Acid Synthesis | Completed | 2010-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01438411 | Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of… | Phase3 | Bile Acid Synthesis Defect | Completed | 2010-01-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT00007020 | Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism … | Phase3 | Infantile Refsum's Disease | Completed | 1992-01-01 | 2009-12-01 | ClinicalTrials.gov |
Total clinical trials: 40
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Delayed Treatment with Brelovitug 300mg | Drug | Phase PHASE3 | Chronic Hepatitis D Infection | ACTIVE_NOT_RECRUITING | NCT07298330 |
| Brelovitug 900 mg | Other | Phase PHASE3 | Chronic Hepatitis D Infection | ACTIVE_NOT_RECRUITING | NCT07298330 |
| Brelovitug 300 mg | Other | Phase PHASE3 | Chronic Hepatitis D Infection | ACTIVE_NOT_RECRUITING | NCT07298330 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Maralixibat | Other | Phase PHASE3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | COMPLETED | NCT04185363 |
| Livmarli Oral Product | Other | Phase PHASE4 | Alagille Syndrome | RECRUITING | NCT07290257 |
| Bulevirtide 2 mg and Brelovitug - 300 mg | Other | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07200908 |
| Brelovitug 300 mg | Other | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07200908 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Livmarli Oral Product | Other | Phase PHASE4 | Alagille Syndrome | RECRUITING | NCT07290257 |
| Maralixibat | Other | Phase PHASE2 | Progressive Familial Intrahepatic Cholestasis | COMPLETED | NCT04729751 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Confirmatory Testing | Other | Preclinical | Acid Sphingomyelinase Deficiency | ENROLLING_BY_INVITATION | NCT05368038 |
| Placebo | Other | Phase PHASE3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | WITHDRAWN | NCT03353454 |
| Maralixibat | Other | Phase PHASE3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | WITHDRAWN | NCT03353454 |
| LUM001 | Other | Phase PHASE2 | Primary Biliary Cirrhosis | WITHDRAWN | NCT02321306 |
| Placebo | Other | Phase PHASE1 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT02287779 |
| SHP626 | Other | Phase PHASE1 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT02287779 |
| Placebo | Other | Phase PHASE2 | Alagille Syndrome | COMPLETED | NCT02057692 |
| LUM001 | Other | Phase PHASE2 | Alagille Syndrome | COMPLETED | NCT02057692 |
| Ursodeoxycholic Acid | Other | Phase PHASE2 | PBC | COMPLETED | NCT01904058 |
| Placebo | Other | Phase PHASE2 | PBC | COMPLETED | NCT01904058 |
| LUM001 | Other | Phase PHASE2 | PBC | COMPLETED | NCT01904058 |
| Placebo | Other | Phase PHASE2 | Alagille Syndrome | COMPLETED | NCT01903460 |
| LUM001 | Other | Phase PHASE2 | Alagille Syndrome | COMPLETED | NCT01903460 |
| LUM001 | Other | Phase PHASE2 | Primary Sclerosing Cholangitis (PSC) | COMPLETED | NCT02061540 |
| Volixibat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02475317 |
| Maralixibat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02475317 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02475317 |
| 5.95 μCi RAD | Other | Phase PHASE1 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT02571192 |
| SHP626 | Other | Phase PHASE1 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT02571192 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis | TERMINATED | NCT02787304 |
| SHP626 | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis | TERMINATED | NCT02787304 |
| LUM001 (Maralixibat) | Other | Phase PHASE2 | Alagille Syndrome | COMPLETED | NCT02117713 |
| Placebo | Other | Phase PHASE2 | Alagille Syndrome | COMPLETED | NCT02160782 |
| LUM001 (Maralixibat) | Other | Phase PHASE2 | Alagille Syndrome | COMPLETED | NCT02160782 |
| maralixibat | Other | Preclinical | Alagille Syndrome | APPROVED_FOR_MARKETING | NCT04530994 |
| LUM001 (Maralixibat) | Other | Phase PHASE2 | Alagille Syndrome | COMPLETED | NCT02047318 |
| Cholbam | Other | Preclinical | Bile Acid Synthesis Disorders | ACTIVE_NOT_RECRUITING | NCT03115086 |
| Cholic Acid | Other | Phase PHASE3 | Bile Acid Synthesis Defect | COMPLETED | NCT01438411 |
| Cholic acid | Other | Phase PHASE3 | Inborn Errors of Bile Acid Synthesis | COMPLETED | NCT01115582 |
| LUM001 (Maralixibat) | Other | Phase PHASE2 | Progressive Familial Intrahepatic Cholestasis (PFIC) | COMPLETED | NCT02057718 |
| Placebo | Other | Phase PHASE3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | COMPLETED | NCT03905330 |
| Maralixibat | Other | Phase PHASE3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | COMPLETED | NCT03905330 |
| Placebo | Other | Phase PHASE2 | Intrahepatic Cholestasis of Pregnancy | TERMINATED | NCT04718961 |
| Volixibat | Other | Phase PHASE2 | Intrahepatic Cholestasis of Pregnancy | TERMINATED | NCT04718961 |
| CDCA Weight-Based Dose TID | Other | Phase PHASE3 | CTX | COMPLETED | NCT04270682 |
| Rescue Medication CDCA 250 mg TID | Drug | Phase PHASE3 | CTX | COMPLETED | NCT04270682 |
| Open-Label CDCA 250 mg TID | Other | Phase PHASE3 | CTX | COMPLETED | NCT04270682 |
| Placebo | Other | Phase PHASE3 | CTX | COMPLETED | NCT04270682 |
| Blinded CDCA 250 mg TID | Other | Phase PHASE3 | CTX | COMPLETED | NCT04270682 |
| Maralixibat | Other | Phase PHASE2 | Progressive Familial Intrahepatic Cholestasis | COMPLETED | NCT04729751 |
| Placebo | Other | Phase PHASE2 | Biliary Atresia | COMPLETED | NCT04524390 |
| Maralixibat | Other | Phase PHASE2 | Biliary Atresia | COMPLETED | NCT04524390 |
| Livmarli | Other | Preclinical | Alagille Syndrome | RECRUITING | NCT06193928 |
| Maralixibat | Other | Phase PHASE3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | COMPLETED | NCT04185363 |
| Maralixibat | Other | Phase PHASE2 | Cholestatic Liver Disease | COMPLETED | NCT04168385 |
| Placebo | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | ACTIVE_NOT_RECRUITING | NCT04663308 |
| Volixibat | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | ACTIVE_NOT_RECRUITING | NCT04663308 |
| Delayed Treatment with Brelovitug 300mg | Drug | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07298330 |
| Brelovitug 900 mg | Other | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07298330 |
| Brelovitug 300 mg | Other | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07298330 |
| Livmarli Oral Product | Other | Phase PHASE4 | Alagille Syndrome | RECRUITING | NCT07290257 |
| Maralixibat | Other | Phase PHASE2 | Intrahepatic Cholestasis of Pregnancy | NOT_YET_RECRUITING | NCT07389031 |
| Delayed Treatment with Brelovitug 300mg | Drug | Phase PHASE2 | Chronic Hepatitis D Infection | ACTIVE_NOT_RECRUITING | NCT06907290 |
| Brelovitug 900 mg | Other | Phase PHASE2 | Chronic Hepatitis D Infection | ACTIVE_NOT_RECRUITING | NCT06907290 |
| Brelovitug 300 mg | Other | Phase PHASE2 | Chronic Hepatitis D Infection | ACTIVE_NOT_RECRUITING | NCT06907290 |
| Bulevirtide 2 mg and Brelovitug - 300 mg | Other | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07200908 |
| Brelovitug 300 mg | Other | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07200908 |
| Placebo | Other | Phase PHASE3 | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | ACTIVE_NOT_RECRUITING | NCT06553768 |
| Maralixibat | Other | Phase PHASE3 | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | ACTIVE_NOT_RECRUITING | NCT06553768 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Volixibat | Other | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 Open-Label | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | Other | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | Other | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Bulevirtide | DRUG | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Brelovitug (BJT-778) | DRUG | Phase PHASE2 | Chronic Hepatitis D | RECRUITING | NCT07454837 |
| Livmarli Oral Product | DRUG | Phase PHASE4 | Alagille Syndrome | RECRUITING | NCT07290257 |
| Low dose of MRM-3379 Open-Label | DRUG | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| High dose of MRM-3379 | DRUG | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Middle Dose of MRM-3379 | DRUG | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Low dose of MRM-3379 | DRUG | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| Bulevirtide 2 mg and Brelovitug - 300 mg | DRUG | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07200908 |
| Delayed Treatment with Brelovitug 300mg | DRUG | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07298330 |
| Brelovitug 900 mg | DRUG | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07298330 |
| Brelovitug 300 mg | DRUG | Phase PHASE3 | Chronic Hepatitis D Infection | RECRUITING | NCT07298330 |
| Livmarli | DRUG | Preclinical | Alagille Syndrome | RECRUITING | NCT06193928 |
| maralixibat | DRUG | Preclinical | Alagille Syndrome | APPROVED_FOR_MARKETING | NCT04530994 |
| CDCA Weight-Based Dose TID | DRUG | Phase PHASE3 | CTX | COMPLETED | NCT04270682 |
| Rescue Medication CDCA 250 mg TID | DRUG | Phase PHASE3 | CTX | COMPLETED | NCT04270682 |
| Open-Label CDCA 250 mg TID | DRUG | Phase PHASE3 | CTX | COMPLETED | NCT04270682 |
| Blinded CDCA 250 mg TID | DRUG | Phase PHASE3 | CTX | COMPLETED | NCT04270682 |
| Cholbam | DRUG | Preclinical | Bile Acid Synthesis Disorders | ACTIVE_NOT_RECRUITING | NCT03115086 |
| 5.95 μCi RAD | RADIATION | Phase PHASE1 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT02571192 |
| Volixibat | DRUG | Phase PHASE2 | Primary Biliary Cholangitis | RECRUITING | NCT05050136 |
| Maralixibat | DRUG | Phase PHASE2 | Intrahepatic Cholestasis of Pregnancy | NOT_YET_RECRUITING | NCT07389031 |
| SHP626 | DRUG | Phase PHASE2 | Non-Alcoholic Steatohepatitis | TERMINATED | NCT02787304 |
| LUM001 (Maralixibat) | DRUG | Phase PHASE2 | Alagille Syndrome | COMPLETED | NCT02160782 |
| Ursodeoxycholic Acid | DRUG | Phase PHASE2 | PBC | COMPLETED | NCT01904058 |
| Placebo | DRUG | Phase PHASE2 | Fragile X Syndrome | RECRUITING | NCT07209462 |
| LUM001 | DRUG | Phase PHASE2 | Primary Biliary Cirrhosis | WITHDRAWN | NCT02321306 |
| Cholic Acid | DRUG | Phase PHASE3 | Bile Acid Synthesis Defect | COMPLETED | NCT01438411 |
| Cholic acid | DRUG | Phase PHASE3 | Inborn Errors of Bile Acid Synthesis | COMPLETED | NCT01115582 |
| Cholic Acids | DRUG | Phase PHASE3 | Infantile Refsum's Disease | COMPLETED | NCT00007020 |
Total products: 255